Regulatory
Conference call and webcast (in English) today, May 14, 2019 at 3:00 pm CET / 9:00 am EST
Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings
Under the terms of the deal, AbbVie will grant Germany-based Boehringer Ingelheim a non-exclusive license for Cyltezo, its biosimilar to Humira.
May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look.
MyoKardia, Inc. reported financial results for the quarter ended March 31, 2019.
Neos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019 and provided a business update.
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease.
Expedeon AG reported results for the first quarter ended March 31, 2019.
Assertio Therapeutics, Inc. reported financial results for the quarter ended March 31, 2019, and provided an update on its business performance and strategic initiatives.
TLC announced financial results for the first quarter ended March 31, 2019, and provided a business update.
PRESS RELEASES